Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Harris & Harris Group Notes Amgen to Acquire BioVex

Abstract:
Harris & Harris Group, Inc. (NASDAQ: TINY) notes that Amgen and BioVex Group, Inc., today announced that the companies have entered into a definitive acquisition agreement under which Amgen has agreed to acquire BioVex Group, a privately held, venture-funded, biotechnology company headquartered in Woburn, Mass. BioVex Group is developing OncoVEXGM-CSF, a novel oncolytic vaccine in Phase 3 clinical development, that may represent a new approach to treating melanoma and head and neck cancer.

Harris & Harris Group Notes Amgen to Acquire BioVex

New York, NY | Posted on January 25th, 2011

Under terms of the agreement, Amgen will pay up to $1 billion: $425 million in cash at closing and up to $575 million in additional payments upon the achievement of certain regulatory and sales milestones. The transaction has been approved by the boards of directors of each company. It is subject to customary closing conditions, including regulatory approvals, and is expected to close in the first quarter of 2011.

Following the completion of the transaction, BioVex Group will become a wholly owned subsidiary of Amgen.

Harris & Harris Group is an investor in privately held BioVex Group. Harris & Harris Group made its initial investment in BioVex Group in September 2007.

This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2009, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The reference to the website www.HHVC.com has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.

####

About Harris & Harris Group
Harris & Harris Group is a publicly traded venture capital company that invests in nanotechnology and microsystems. Detailed information about Harris & Harris Group and its holdings can be found on its website at www.HHVC.com.

For more information, please click here

Copyright © Harris & Harris Group

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Moving diagnostics out of the lab and into your hand: Electrochemical sensor platform technology could enable portable, multiplexed, point-of-care diagnostics for a wide range of applications November 11th, 2019

Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Year End Results November 11th, 2019

Scientists probe the limits of ice: Transition between ice and liquid water gets fuzzy at the nanoscale November 9th, 2019

Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019 November 8th, 2019

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Year End Results November 11th, 2019

Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019 November 8th, 2019

Nanoparticle orientation offers a way to enhance drug delivery: Coating particles with 'right-handed' molecules could help them penetrate cancer cells more easily November 5th, 2019

Picosun expands selection of biocompatible ALD materials for medical applications November 4th, 2019

Announcements

Moving diagnostics out of the lab and into your hand: Electrochemical sensor platform technology could enable portable, multiplexed, point-of-care diagnostics for a wide range of applications November 11th, 2019

Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Year End Results November 11th, 2019

Scientists probe the limits of ice: Transition between ice and liquid water gets fuzzy at the nanoscale November 9th, 2019

A distinct spin on atomic transport: Work that demonstrates simultaneous control over transport and spin properties of cold atoms establishes a framework for exploring concepts of spintronics and solid-state physics November 8th, 2019

Nanobiotechnology

Moving diagnostics out of the lab and into your hand: Electrochemical sensor platform technology could enable portable, multiplexed, point-of-care diagnostics for a wide range of applications November 11th, 2019

Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Year End Results November 11th, 2019

Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019 November 8th, 2019

Nanoparticle orientation offers a way to enhance drug delivery: Coating particles with 'right-handed' molecules could help them penetrate cancer cells more easily November 5th, 2019

Acquisitions/Mergers/Splits

Combination of Nanometrics and Rudolph Technologies to Create Onto Innovation October 16th, 2019

GLOBALFOUNDRIES Acquires Smartcom’s PDK Engineering Team to Expand Worldwide Design Enablement Capacity: Acquisition strengthens overall process design capabilities and expands the company’s footprint in Europe October 11th, 2019

VIS To Acquire GLOBALFOUNDRIES’ Fab 3E In Singapore February 1st, 2019

180 Degree Capital Corp.’s Portfolio Company, TheStreet, Inc., Agrees to Sell Its Institutional Business Units to Euromoney Institutional Investor PLC for $87.3 Million December 6th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project